Immunosuppressants Stocks List

Recent Signals

Date Stock Signal Type
2021-04-12 AUPH NR7 Range Contraction
2021-04-12 BIIB Stochastic Reached Oversold Weakness
2021-04-12 BIIB MACD Bearish Centerline Cross Bearish
2021-04-12 BIIB 180 Bearish Setup Bearish Swing Setup
2021-04-12 CANF 50 DMA Support Bullish
2021-04-12 CCXI Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-12 CCXI Expansion Breakdown Bearish Swing Setup
2021-04-12 CCXI Reversal New Lows Setup Bearish Swing Setup
2021-04-12 CHRS New 52 Week Closing Low Bearish
2021-04-12 CHRS New 52 Week Low Weakness
2021-04-12 TEVA MACD Bearish Centerline Cross Bearish
2021-04-12 TEVA Stochastic Reached Oversold Weakness
2021-04-12 TEVA NR7-2 Range Contraction
2021-04-12 TEVA NR7 Range Contraction
2021-04-12 TEVA Bollinger Band Squeeze Range Contraction

Recent News for Immunosuppressants Stocks

Date Stock Title
Apr 12 BIIB Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen
Apr 12 BIIB Biogen and Sage trade lower despite positive essential tremor trial
Apr 12 BIIB Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out
Apr 12 BIIB Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered Drug
Apr 12 BIIB Sage Therapeutics/Biogen's SAGE-324 meets primary endpoint in essential tremor study
Apr 12 BIIB Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Apr 9 BIIB Biogen Announces Two New Nominees for Election to Board of Directors
Apr 9 BIIB Provention Bio downgraded on FDA feedback, Citi sizes up Zuranolone success on Sage, and more in today’s analyst action
Apr 9 CCXI ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting
Apr 8 BIIB Biotech Stocks Could Use A Win — Will The First Quarter Offer That?
Apr 8 BIIB Is It Too Late to Buy Biogen (BIIB) Stock?
Apr 8 BIIB Biogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid Arthritis
Apr 8 BIIB Biogen inks BAT1806 licensing deal in rheumatoid arthritis
Apr 8 TEVA Teva’s Seffalair And BroPair Spiromax Receive Approval In EU
Apr 8 AUPH Aurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data Shows
Apr 8 TEVA Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults
Apr 8 AUPH Aurinia presents additional data highlighting benefit of lupus nephritis therapy
Apr 8 BIIB Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
Apr 8 AUPH Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
Apr 8 TEVA EU authorizes Teva's Seffalair and BroPair Spiromax for asthma

Immunosuppression is a reduction of the activation or efficacy of the immune system. Some portions of the immune system itself have immunosuppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.In general, deliberately induced immunosuppression is performed to prevent the body from rejecting an organ transplant. Additionally, it is used for treating graft-versus-host disease after a bone marrow transplant, or for the treatment of auto-immune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, or Crohn's disease. This is typically done using medications, but may involve surgery (splenectomy), plasmapheresis, or radiation. A person who is undergoing immunosuppression, or whose immune system is weak for some other reasons (chemotherapy or HIV), is said to be immunocompromised.

More about Immunosuppressants
Browse All Tags